Ivergalen

Ivermectin, the active ingredient in Ivergalen, is an anthelmintic (macrocyclic lactone) presented as an oral tablet for systemic use. It is employed to treat parasitic infections such as onchocerciasis, strongyloidiasis, scabies and pediculosis in appropriate patient populations.

GNH USA supplies Ivergalen as a licensed, GDP‑compliant international pharmaceutical supplier, adhering to EU manufacturing standards and providing the product to hospitals, pharmacies and clinics worldwide through regulated distribution channels. All batches undergo rigorous quality testing to ensure potency and safety in accordance with pharmacopeial specifications.

Ivermectin is an anthelmintic used to treat several parasitic infections. - Onchocerciasis: reduces microfilarial load and prevents disease progression. - Strongyloidiasis: eradicates intestinal larvae and prevents hyperinfection. - Scabies: eliminates Sarcoptes scabiei mites, relieving skin lesions. - Pediculosis: kills head lice, controlling infestation.

Adverse reactions may occur with ivermectin therapy.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Dizziness: transient light‑headedness. - Abdominal pain: cramping or discomfort. - Diarrhea: loose stools. - Pruritus: mild skin itching. - Headache: mild to moderate.

Serious or Rare Side Effects: - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatotoxicity: elevated liver enzymes or liver injury. - Neurologic toxicity: seizures, ataxia, or altered consciousness. - Hypotension: marked drop in blood pressure. - Anaphylaxis: acute allergic reaction requiring emergency care.

Safety considerations should be observed before prescribing ivermectin. - Pregnancy: safety not established; use only if benefit outweighs risk. - Breastfeeding: unknown excretion; consider potential infant exposure. - Liver disease: use with caution and monitor hepatic function. - Concomitant CNS depressants: may increase neurotoxicity risk. - Drug interactions: review for strong CYP3A4 inhibitors and P‑gp inhibitors. - Store at ambient temperature: keep in original container, protect from moisture and light.

Ivermectin may interact with other medicines; review patient medication lists.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise ivermectin plasma levels. - P‑glycoprotein inhibitors: increase central nervous system exposure. - Warfarin: potential enhancement of anticoagulant effect.

Moderate Interactions (Monitor Closely): - Anticonvulsants (e.g., carbamazepine): may reduce ivermectin efficacy. - Macrolide antibiotics: moderate effect on metabolism. - Alcohol: may augment CNS depression.